VYNE Therapeutics Inc.
VYNE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.01 | 0.00 | 0.01 |
| FCF Yield | -23.89% | -105.87% | -339.45% | -107.38% |
| EV / EBITDA | -2.82 | 0.22 | 0.66 | -0.27 |
| Quality | ||||
| ROIC | -83.63% | -32.41% | -109.22% | -137.06% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 77.31% |
| Cash Conversion Ratio | 0.85 | 0.89 | 1.26 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.65% | -23.06% | -71.68% | 28.09% |
| Free Cash Flow Growth | -34.52% | 13.22% | 48.20% | 58.91% |
| Safety | ||||
| Net Debt / EBITDA | 0.45 | 1.04 | 0.91 | 1.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -12.13 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.46 |
| Cash Conversion Cycle | 0.00 | 0.00 | 3,826.00 | 272.73 |